Sign In
Buy TRIB
$11.60
-1.15 (-9.02%)
At Close: Jul 31, 2026
Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology
07:20am, Tuesday, 28'th Jan 2025
Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 Trinity Biotech's patented technology represents a paradigm shift in
Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan
08:33am, Tuesday, 24'th Dec 2024
DUBLIN, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearabl
Trinity Biotech Receives Early Approval from the World Health Organization to Begin Offshore Manufacturing of TrinScreen HIV & Uni-Gold HIV
11:00am, Wednesday, 18'th Dec 2024
DUBLIN, Ireland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, includin
Trinity Biotech Plc (TRIB) Q3 2024 Earnings Call Transcript
12:37pm, Friday, 15'th Nov 2024
Trinity Biotech Plc (NASDAQ:TRIB ) Q3 2024 Earnings Conference Call November 15, 2024 10:00 AM ET Company Participants Eric Ribner - Investor Relations John Gillard – President, Chief Executive Offi
Trinity Biotech Announces Q3 2024 Financial Results
09:00am, Friday, 15'th Nov 2024
Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV business Point-of-Care product revenue of $4.3 million grew 60% Y/Y Reiterates guidance to a
Trinity Biotech to Announce Q3 2024 Financial Results
08:07am, Thursday, 14'th Nov 2024
Conference Call Scheduled for Friday, November 15, 2024 at 10:00 AM ET Conference Call Scheduled for Friday, November 15, 2024 at 10:00 AM ET
Trinity Biotech Regains Compliance with Nasdaq Listing Requirements
08:19am, Thursday, 07'th Nov 2024
DUBLIN, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq Global Select: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, inc
Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture
08:45am, Friday, 25'th Oct 2024
DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearabl
Trinity Biotech Announces Strategic Investment in Novus Diagnostics to Advance Rapid Sepsis Testing Platform
08:45am, Friday, 25'th Oct 2024
DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearabl
Trinity Biotech Shares Surge on Positive Pre-Pivotal Clinical CGM Trial
02:25pm, Tuesday, 08'th Oct 2024
TRIB announces positive results from its pre-pivotal clinical European trial for a next-gen continuous glucose monitor, setting the stage for further development in 2025.
Trinity Biotech Announces Positive Pre-Pivotal Trial Results for Its Next-Generation Continuous Glucose Monitor Technology
08:15am, Monday, 07'th Oct 2024
DUBLIN, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearabl
Trinity Biotech's Stock Rises After Acquisition of Metabolomics
11:45am, Wednesday, 25'th Sep 2024
TRIB acquires Metabolomics Diagnostics, expanding its platform with cutting-edge tech to enhance diagnostics in maternal health and diabetes management.
Trinity Biotech Announces Acquisition of Metabolomics Diagnostics to Grow Presence in Maternal Health Market
04:05pm, Tuesday, 24'th Sep 2024
-Metabolomics Diagnostics, a deep-tech machine learning diagnostic platform developer, has developed an innovative test, PrePsia, to accurately predict the risk of preeclampsia in pregnant women-
Trinity Biotech to Initiate CGM Market Study in India in Furtherance of Intended Collaboration with Bayer
04:05pm, Wednesday, 18'th Sep 2024
DUBLIN, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearab
Will Trinity Biotech Stock Gain From Its Latest Patent Process?
10:10am, Tuesday, 10'th Sep 2024
TRIB announces updates on its European patented process. The company aims to use this process to improve the functionality of its glucose biosensor in its next-gen CGM technology.
